Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Codexis, Inc.NASDAQ: CDXS

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense growth accelerates

Q1 FY2026 income tax expense of $36K rose 227.3% year over year, ahead of the +111.8% change in trailing-twelve-month income tax expense. Sequentially, it rose 100.0% from the prior quarter. Over 3 fiscal years it compounded at -44.6% a year.

Context

  • Income tax expense amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +227.3% holds above the trailing-twelve-month pace of +111.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$36K+100.0% QoQ
Last fiscal yearDec 2025
$47K+38.2% YoY
LTMMar 2026
$72K+111.8% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+227.3%——
1 year+38.2%——
3-year CAGR-44.6%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
47K USD
Year-over-year change
+38.2%
4-year CAGR
-29.4%

Income Tax Expense vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +111.8% is the 2nd highest of 4, against a peer median of -7.6%.
  • Income tax expense amounts to 0.1% of revenue for CDXS, versus a peer median of 0.0%.
CDXS Competitors
Income Tax Expense for CDXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OABIOmniAb, Inc.LTM Mar 2026$913K USD+113.3%—3.2%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$121K USD-7.6%—0.3%
CDXSCodexis, Inc.LTM Mar 2026$72K USD+111.8%-44.6%0.1%
IVVDInvivyd, Inc.LTM Mar 2026$0 USD——0.0%
TARAProtara Therapeutics, Inc.LTM Mar 2026$0 USD———
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$0 USD——0.0%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$0 USD——0.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-$687K USD-370.5%—2.0%
Peer median (excluding CDXS) —-7.6%—0.0%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue104.75M138.59M70.14M59.35M70.39M
Cost of Revenue22.21M38.03M12.81M16.29M9.34M
Gross Profit82.55M100.56M57.33M43.06M61.05M
Gross Margin78.8%72.6%81.7%72.6%86.7%
Research & Development55.92M80.1M58.89M46.26M52.31M
Selling, General & Admin49.32M52.17M53.25M55.15M47.07M
Operating Expenses105.24M135.44M125.4M101.58M99.38M
Depreciation & Amortization5.95M5.4M5.52M4.95M5.25M
EBITDA(15.14M)(26.31M)(49.28M)(53.41M)(33.87M)
EBITDA Margin-14.5%-19.0%-70.3%-90.0%-48.1%
Operating Income(22.7M)(34.88M)(68.07M)(58.52M)(38.33M)
Operating Margin-21.7%-25.2%-97.0%-98.6%-54.5%
Interest Income459K1.44M4.17M3.67M2.63M
Interest Expense00004.81M
Other Income / Expenses1.61M1.57M(8.1M)(6.72M)(5.6M)
Income Before Tax(21.09M)(33.32M)(76.17M)(65.24M)(43.93M)
Pre-Tax Margin-20.1%-24.0%-108.6%-109.9%-62.4%
Income Tax Expense189K276K69K34K47K
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Net Margin-20.3%-24.2%-108.7%-110.0%-62.5%
EPS (Basic)(0.33)(0.51)(1.12)(0.89)(0.50)
EPS (Diluted)(0.33)(0.51)(1.12)(0.89)(0.50)
Weighted Avg Shares64.57M65.34M68.13M73.41M87.14M
Weighted Avg Shares (Diluted)64.57M65.34M68.13M73.41M87.14M

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.